102 results on '"Angles-Cano, E."'
Search Results
2. Development of an LC-MRM-MS-based candidate reference measurement procedure for standardization of serum apolipoprotein (a) tests
3. Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain
4. Towards an SI-traceable reference measurement system for serum apolipoproteins (A), A-I, B, C-I, C-II, C-III and E
5. Towards SI-traceability of lipoprotein (a) measurements: Comparison of a candidate LC-MRM-MS RMP method with commercially available immunoassays for evaluating commutability of candidate reference materials
6. Apo(a) phenotyping and long-term prognosis for coronary artery disease
7. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques
8. Fibrinolytic activity of microvesicles: a compensatory mechanism in clot formation/dissolution: O1.3.05
9. Synergistic effect of thrombin and CD40I on endothelial MMP-10 expression and microparticle generation in vitro and in vivo: O2.4.04
10. MMP-10 as a new profibrinolytic agent in experimental stroke through TAFI-mediated mechanism: O1.2.02
11. UNVEILING AN EXCEPTIONAL ZYMOGEN: THE SINGLE-CHAIN FORM OF TPA IS A SELECTIVE ACTIVATOR OF NMDAR SIGNALING: 3
12. Brain plasminogen system: O14B-4
13. Neurovascular-derived microparticles: potential biomarkers and fibrinolytic messenger in stroke: O14B-1
14. Novel in vivo and in vitro profibrinolytic effect of MMP-10 mediated by TAFI: O2A-4
15. In vivo and in vitro profibrinolytic effect of MMP-10 mediated by TAFI: a new role for MMPs on fibrinolysis?: OC-TH-113
16. Endothelial microparticles plasmin generation: a new mechanism regulating endothelium proteolytic activities: AS-WE-050
17. A new thromboembolic stroke model in the anaesthetized mouse: O6–02
18. M265 Towards SI-traceability of lipoprotein (A) measurements: Comparison of a candidate LC-MRM-MS RMP method with commercially available immunoassays for evaluating commutability of candidate reference materials
19. M264 Towards an SI-traceable LC-MRM-MS based candidate reference measurement procedure for multiplex measurement of serum apolipoproteins (A), A-I, B, C-I, C-II, C-III and E
20. Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.
21. In transition to the next generation reference materials and reference measurement procedures for apolipoprotein standardization
22. A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping
23. Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitor-Mediated Mechanism.
24. VASCULAR SMOOTH MUSCLE CELL APOPTOSIS IN ATHEROSCLEROTIC PLAQUES IS MEDIATED BY PLASMINOGEN ACTIVATION.
25. The activation of plasminogen by tissue plasminogen activator is not enhanced by different heparin species as assessed in vitro with a solid-phase fibrin method
26. Neutralization of plasminogen activator inhibitor-1 (PAI-1) by activated protein C is species-dependent
27. A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single chain urokinase and sequential combinations of the activators
28. Development of an internal standard for plasminogen activator inhibitor-1 PAI-1 and its use in a simplified assay for measuring pai-1 activity in human plasma
29. Functional identification of t-PA in crude and purified systems
30. A method for the determination of the affinity constant of antibodies to tissue plasminogen activator
31. Release of VIII R:Ag and VIII R:WF during thrombin and collagen induced aggregation
32. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor
33. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
34. Enhanced Plasminogen-Activator Production by Leukocytes in the Human and Murine Chediak-Higashi Syndrome
35. Plasma levels of single-chain urokinase in the elderly
36. Solid-phase fibrin-tissue-plasminogen-activator activity assay (sofia-TPA): TPA but not uk is specifically detected
37. 152 A monoclonal antibody to the lbs of apo(a) inhibits binding of apo(a) but not plasminogen to fibrin
38. Influence of continuous infusion of prostacyclin on plasma levels of t-PA, PAI-1 and vWF in primary pulmonary hypertension
39. Binding of glu-plasminogen to fibrin by a two sites interaction plays an essential role in fibrinolysis
40. Functional heterogeneity of lipoprotein(a): Cardiovascular risk in heterozygous subjects is linked to APO(a) isoforms
41. Studies on hementerin, a fibrinogenolytic protein isolated from the salivary complex of the leech Haementeria depressa
42. Two-chain urokinase inactivates human α-thrombin
43. 393 changes in fibrinolysis during liver transplantation (LT)
44. 328 Plasminogen activation by fibrin-bound tPA in a plasma environment: Role of alpha-2-antiplasmin
45. 130 Activated protein C-induced increase of tissue plasminogen activator (tPA) activity in human plasma: Evidence for the quenching of tPA-inhibitor (PAI-1) and for the interaction with tPA-PAI complexes
46. 124 Studies on the interaction of tissue plasminogen activator (tPA) with its inhibitor (PAI-1) and fibrin
47. 123 Studies on the latency of tissue plasminogen activator-inhibitor (PAI-1) and on the SDS stability of tPA-PAI complexes
48. Slow and fast contracting rat skeletal muscles differ in plasminogen activator activities
49. Markers of endothelial involvement in chronic pulmonary hypertension
50. The vascular plasminogen activator activity present in human plasma after venous occlusion circulates as a vPA-inhibitor complex
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.